A business plan to help the 'global South' in its fight against neglected diseases.
暂无分享,去创建一个
[1] Mary Moran,et al. A Breakthrough in R&D for Neglected Diseases: New Ways to Get the Drugs We Need , 2005, PLoS Medicine.
[2] D. Wirth,et al. Drugs for neglected diseases: a failure of the market and a public health failure? , 2001, Tropical medicine & international health : TM & IH.
[3] Jaideep P. Sundaram,et al. Health Innovation Networks to Help Developing Countries Address Neglected Diseases , 2005, Science.
[4] J. Guzman,et al. Neglected Disease Research and Development: How Much Are We Really Spending? , 2009, PLoS medicine.
[5] B. Thylefors,et al. Towards the elimination of onchocerciasis , 2006, Annals of tropical medicine and parasitology.
[6] Peter A Singer,et al. Small but tenacious: South Africa's health biotech sector , 2009, Nature Biotechnology.
[7] India's health biotech sector at a crossroads , 2007, Nature Biotechnology.
[8] P. Singer,et al. The Indian and Chinese health biotechnology industries: potential champions of global health? , 2008, Health affairs.
[9] Els Torreele,et al. Drug development for neglected diseases: a deficient market and a public-health policy failure , 2002, The Lancet.
[10] A. Daar,et al. Brazilian health biotech—fostering crosstalk between public and private sectors , 2008, Nature Biotechnology.
[11] D. Durrheim,et al. Current Concepts Control of Neglected Tropical Diseases , 2007 .
[12] E. Torreele,et al. Global framework on essential health R&D , 2006, The Lancet.
[13] A. Daar,et al. Chinese health biotech and the billion-patient market , 2008, Nature Biotechnology.